The Efficacy of Posterior Subtenon Triamcinolone Acetonide Injection in Treatment of Irvine-Gass Syndrome

ABSTRACT

Purpose: To evaluate the efficacy and safety of posterior 40 mg subtenon triamcinolone acetonide (PST) injection in treating Irvine-Gass syndrome.

Methods: The retrospective study included 21 patients (mean age: 76 ± 8.2) with a treatment-naïve eye subjected to topical anesthesia and injection of 40 mg/ml triamcinolone via a blunt tip SubTenon cannula through a single inferonasal peritomy. Best corrected visual acuity (BCVA; logMAR), intraocular pressure (IOP), biomicroscopic and funduscopic findings, and optical coherence tomography (OCT) measurements were recorded.

Results: Baseline central macular thickness decreased from 431 ± 136 µm to 300 ± 67 µm (1st month; p = .002), to 292 ± 56 µm (3rd month; p = .002), and to 299 ± 66 µm (6th month; p = .005). Mean BCVA increased from 0.71 ± 0.23 to 0.27 ± 0.11, 0.19 ± 0.06, and 0.24 ± 0.17, respectively (all visits; p < 0.001). Mean IOP values did not change significantly (p = .12).

Conclusion: PST injection is an effective and safe treatment for Irvine-Gass syndrome.

Keywords:

• corticosteroids
• irvine-gass syndrome
• posterior subtenon
• pseudophakic macular edema
• triamcinolone

DISCLOSURE OF INTEREST

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this study.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author, [B.E.], upon reasonable request.

Additional information

Funding

The authors have no financial supports or other benefits from commercial sources for the work reported on in the manuscript.